期刊
JOURNAL OF THORACIC ONCOLOGY
卷 10, 期 1, 页码 S1-S63出版社
ELSEVIER SCIENCE INC
DOI: 10.1097/JTO.0000000000000405
关键词
Non-small-cell lung cancer; Targeted therapies; Immunotherapy
资金
- NATIONAL CANCER INSTITUTE [R21CA170063, R01CA182746, P30CA006973, T32CA009071, K12CA167540, K12CA157688, K23CA149079] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000142] Funding Source: NIH RePORTER
- NCATS NIH HHS [UL1 TR000142] Funding Source: Medline
- NCI NIH HHS [K23 CA149079, K12 CA167540, R21 CA170063, R01 CA182746, P30 CA006973, T32 CA009071] Funding Source: Medline
There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据